Core Viewpoint - TC BioPharm has received formal approval for a special stock dividend of 0.25 American Depositary Shares (ADSs) for every 1 ADS held by shareholders, with expected delivery on or about January 6, 2025 [1][5]. Group 1: Special Dividend Announcement - The special dividend of 0.25 ADSs per 1 ADS will be distributed to shareholders on the record date of January 2, 2025 [1]. - Trading of the Company's ADSs will temporarily halt at 5:00 pm on January 2, 2025, and is expected to resume around January 8, 2025, to facilitate the processing of the stock dividend [2]. Group 2: Company Overview - TC BioPharm is a clinical-stage biotechnology company specializing in gamma-delta T cell therapies for cancer treatment, being the first to conduct phase II/pivotal clinical studies in oncology [3][7]. - The company is currently conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, including a Phase 2b/3 pivotal trial for treating acute myeloid leukemia using proprietary CryoTC technology [3]. Group 3: Management's Perspective - The CEO of TC BioPharm, Bryan Kobel, emphasized that the special dividend is a key part of the company's capital management strategy and reflects management's confidence in the company's financial future, anticipating growth in 2025 [6].
TCBP Issues 25% Stock Dividend